L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 151096-09-2 REGISTRY
ED Entered STN: 10 Nov 1993
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, (4aS-cis)-
CN 6H-Pyrrolo[3,4-b]pyridine, 3-quinolinecarboxylic acid deriv.
OTHER NAMES:
CN Izilox
CN Moxifloxacin
CN Moxifloxacine
CN Vigamox
FS STEREOSEARCH
DR 195154-07-5
MF C21 H24 F N3 O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1826 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1834 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l2
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 186826-86-8 REGISTRY

```
ED   Entered STN:  07 Mar 1997
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-, hydrochloride
     (1:1)   (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     (octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-, monohydrochloride,
     (4aS-cis)-
CN   3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-
     [(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-,
     monohydrochloride (9CI)
OTHER NAMES:
CN   Actira
CN   Avalox
CN   Avelox
CN   BAY 12-8039
CN   Lapinix
CN   Moxifloxacin hydrochloride
CN   Octegra
FS   STEREOSEARCH
MF   C21 H24 F N3 O4 . Cl H
CI   COM
SR   CA
LC   STN Files:   ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS,
       EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR,
       PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
CRN  (151096-09-2)

Absolute stereochemistry.  Rotation (-).
```



● HCl

```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             105 REFERENCES IN FILE CA (1907 TO DATE)
             106 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d his l5

     (FILE 'CAPLUS' ENTERED AT 17:30:09 ON 27 OCT 2008)
L5           106 S L2

=> d his l7
```

```
     (FILE 'CAPLUS' ENTERED AT 17:30:09 ON 27 OCT 2008)
L7            18 S L5 AND US/PC

=> d his l8

     (FILE 'CAPLUS' ENTERED AT 17:30:09 ON 27 OCT 2008)
L8             4 S L7 AND CRYSTAL?

     FILE 'REGISTRY' ENTERED AT 17:32:54 ON 27 OCT 2008

     FILE 'CAPLUS' ENTERED AT 17:32:54 ON 27 OCT 2008

     FILE 'STNGUIDE' ENTERED AT 17:33:51 ON 27 OCT 2008

     FILE 'REGISTRY' ENTERED AT 17:34:23 ON 27 OCT 2008

     FILE 'STNGUIDE' ENTERED AT 17:34:24 ON 27 OCT 2008

     FILE 'REGISTRY' ENTERED AT 17:34:28 ON 27 OCT 2008

     FILE 'STNGUIDE' ENTERED AT 17:34:28 ON 27 OCT 2008

=> d bib hit 1-4
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y



L8   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:523453  CAPLUS
DN   143:48135
TI   Process for the preparation of polymorphic crystalline forms of
     the antibiotic moxifloxacin hydrochloride
IN   Turchetta, Stefano; Massardo, Pietro; Aromatario, Valentina
PA   Chemi S.p.A., Italy
SO   PCT Int. Appl., 34 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005054240       A1     20050616    WO 2004-EP52699        20041028
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
              SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
              SN, TD, TG
     EP 1685130          A1     20060802    EP 2004-791330         20041028
          R:  DE, ES, FR, GB, IT
     JP 2007511580       T      20070510    JP 2006-540424         20041028
     US 20070072895      A1     20070329    US 2006-580173         20060522 <--
PRAI IT 2003-MI2259      A      20031120
     US 2003-532779P     P      20031224
```

WO 2004-EP52699 W 20041028
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
TI Process for the preparation of polymorphic crystalline forms of the antibiotic moxifloxacin hydrochloride

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005054240	A1	20050616	WO 2004-EP52699	20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1685130	A1	20060802	EP 2004-791330	20041028
R: DE, ES, FR, GB, IT				
JP 2007511580	T	20070510	JP 2006-540424	20041028
US 20070072895	A1	20070329	US 2006-580173	20060522 <--

AB A process for the preparation of polymorphic crystalline forms of the antibiotic moxifloxacin hydrochloride comprises: (A) suspending moxifloxacin hydrochloride in a solvent selected from an alc. and a polyalc.; (B) heating the mixture under reflux; (C) cooling; (D) isolating the product which is separated (crystal form A); and addnl., (E) reslurrying the solid at reflux in a solvent selected from alcs. and polyols, or their mixts. thereof, in which the resulting mixture has an overall water content of between 2.5% and 0.01% by weight; and (F) isolating the product (crystal form B). These moxifloxacin hydrochloride polymorphic crystalline forms have increased stability for use in pharmaceutical formulations.
ST moxifloxacin hydrochloride crystal polymorphism prepn
IT Antibiotics
Polymorphism (crystal)
(process for the preparation of polymorphic crystalline forms of the antibiotic moxifloxacin hydrochloride)
IT 186826-86-8, Moxifloxacin hydrochloride 192927-63-2, Moxifloxacin hydrochloride monohydrate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(process for the preparation of polymorphic crystalline forms of the antibiotic moxifloxacin hydrochloride)

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:902187 CAPLUS
DN 141:370574
TI Preparation of a crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof
IN Reddy, Manne Satyanarayana; Eswaraiah, Sajja; Raju, Vetukuri Venkata Naga Kali Vara Prasada; Kumar, Rapolu Rajesh; Srinivasreddy, Ningam; Ravindra, Vedantham
PA Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091619	A1	20041028	WO 2004-US11031	20040409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2003MA00308	A	20050304	IN 2003-MA308	20030409
	CA 2521398	A1	20041028	CA 2004-2521398	20040409
	US 20050137227	A1	20050623	US 2004-822154	20040409 <--
	US 7230006	B2	20070612		
	EP 1615645	A1	20060118	EP 2004-759378	20040409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	IN 2005CN02833	A	20060210	IN 2005-CN2833	20051031
PRAI	IN 2003-MA308	A	20030409		
	WO 2004-US11031	W	20040409		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Preparation of a crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091619	A1	20041028	WO 2004-US11031	20040409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2003MA00308	A	20050304	IN 2003-MA308	20030409
	CA 2521398	A1	20041028	CA 2004-2521398	20040409
	US 20050137227	A1	20050623	US 2004-822154	20040409 <--
	US 7230006	B2	20070612		
	EP 1615645	A1	20060118	EP 2004-759378	20040409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	IN 2005CN02833	A	20060210	IN 2005-CN2833	20051031

IT Crystal structure
Polymorphism (crystal)
(of crystalline form III of anhydrous moxifloxacin hydrochloride)

IT 151096-09-2P, Moxifloxacin 186826-86-8P, Moxifloxacin hydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystalline form III of anhydrous moxifloxacin hydrochloride)

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:390247 CAPLUS
DN 140:412313
TI Process for the preparation of amorphous moxifloxacin hydrochloride
IN Biswas, Sujay; Bose, Prosenjit; Kumar, Yatendra
PA Ranbaxy Laboratories Limited, India
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039804	A1	20040513	WO 2003-IB4845	20031030
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003278418	A1	20040525	AU 2003-278418	20031030
	EP 1562942	A1	20050817	EP 2003-769724	20031030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20060252789	A1	20061109	US 2005-533246	20050429 <--
	IN 2005DN02579	A	20071221	IN 2005-DN2579	20050614
PRAI	IN 2002-DE1096	A	20021031		
	WO 2003-IB4845	W	20031030		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039804	A1	20040513	WO 2003-IB4845	20031030
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003278418	A1	20040525	AU 2003-278418	20031030
	EP 1562942	A1	20050817	EP 2003-769724	20031030
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20060252789	A1	20061109	US 2005-533246	20050429 <--
	IN 2005DN02579	A	20071221	IN 2005-DN2579	20050614

ST crystal polymorphism moxifloxacin hydrochloride
IT Polymorphism (crystal)
(process for the preparation of amorphous moxifloxacin hydrochloride)
IT 186826-86-8, Moxifloxacin hydrochloride
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(process for the preparation of amorphous moxifloxacin hydrochloride)

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:515377 CAPLUS
DN 127:140545
OREF 127:27017a,27020a
TI Pharmaceuticals containing 1-Cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-cholinecarboxylic acid hydrochloride
IN Grunenberg, Alfons; Bosche, Patrick
PA Bayer A.-G., Germany
SO Ger. Offen., 17 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19546249	A1	19970619	DE 1995-19546249	19951212
	HR 960558	B1	20020430	HR 1996-558	19961125
	RO 119782	B1	20050330	RO 1996-2223	19961125
	EP 780390	A1	19970625	EP 1996-119134	19961129
	EP 780390	B1	20020731		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 221531	T	20020815	AT 1996-119134	19961129
	PT 780390	T	20021129	PT 1996-119134	19961129
	ES 2179910	T3	20030201	ES 1996-119134	19961129
	US 5849752	A	19981215	US 1996-760543	19961205 <--
	AU 9674216	A	19970619	AU 1996-74216	19961206
	AU 708006	B2	19990729		
	TW 411340	B	20001111	TW 1996-85115048	19961206
	IN 185805	A1	20010505	IN 1996-DE2723	19961206
	CA 2192418	A1	19970613	CA 1996-2192418	19961209
	CA 2192418	C	20010612		
	JP 09169757	A	19970630	JP 1996-344502	19961210
	JP 4104687	B2	20080618		
	IL 119795	A	19981227	IL 1996-119795	19961210
	PL 184885	B1	20030131	PL 1996-317415	19961210
	NO 9605298	A	19970613	NO 1996-5298	19961211
	ZA 9610405	A	19970623	ZA 1996-10405	19961211
	BR 9605968	A	19980818	BR 1996-5968	19961211
	RU 2162468	C2	20010127	RU 1996-123410	19961211
	CZ 288657	B6	20010815	CZ 1996-3646	19961211
	EE 3474	B1	20010815	EE 1996-201	19961211
	SK 282805	B6	20021203	SK 1996-1591	19961211
	HU 9603428	A2	19970828	HU 1996-3428	19961212
	HU 9603428	A3	19971028		
	CN 1160052	A	19970924	CN 1996-123220	19961212
	CN 1061348	C	20010131		
PRAI	DE 1995-19546249	A	19951212		

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19546249	A1	19970619	DE 1995-19546249	19951212
	HR 960558	B1	20020430	HR 1996-558	19961125
	RO 119782	B1	20050330	RO 1996-2223	19961125
	EP 780390	A1	19970625	EP 1996-119134	19961129
	EP 780390	B1	20020731		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 221531	T	20020815	AT 1996-119134	19961129

PT	780390	T	20021129	PT 1996-119134	19961129
ES	2179910	T3	20030201	ES 1996-119134	19961129
US	5849752	A	19981215	US 1996-760543	19961205 <--
AU	9674216	A	19970619	AU 1996-74216	19961206
AU	708006	B2	19990729		
TW	411340	B	20001111	TW 1996-85115048	19961206
IN	185805	A1	20010505	IN 1996-DE2723	19961206
CA	2192418	A1	19970613	CA 1996-2192418	19961209
CA	2192418	C	20010612		
JP	09169757	A	19970630	JP 1996-344502	19961210
JP	4104687	B2	20080618		
IL	119795	A	19981227	IL 1996-119795	19961210
PL	184885	B1	20030131	PL 1996-317415	19961210
NO	9605298	A	19970613	NO 1996-5298	19961211
ZA	9610405	A	19970623	ZA 1996-10405	19961211
BR	9605968	A	19980818	BR 1996-5968	19961211
RU	2162468	C2	20010127	RU 1996-123410	19961211
CZ	288657	B6	20010815	CZ 1996-3646	19961211
EE	3474	B1	20010815	EE 1996-201	19961211
SK	282805	B6	20021203	SK 1996-1591	19961211
HU	9603428	A2	19970828	HU 1996-3428	19961212
HU	9603428	A3	19971028		
CN	1160052	A	19970924	CN 1996-123220	19961212
CN	1061348	C	20010131		

AB A method for preparing the monohydrate of the title drug for pharmaceutical compns. is described. Thus, the title drug (1 g) was dissolved in 150 mL EtOH and the solvent was removed at 60°. The prismatic crystals separated were dried at room temperature Tablets were prepared from the monohydrate 25.1 g and common excipients.

IT 186826-86-8
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(pharmaceuticals containing diazabicyclononyldihydrocholinecarboxylate)